Search results
Results from the WOW.Com Content Network
On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for sustained long-term growth and innovations in structural heart therapies.
Edwards lifted its 2023 sales forecast to between $5.9 billion and $6.1 billion, from $5.6 billion to $6.0 billion estimated earlier. The new mid-point is slightly higher than analysts' estimates ...
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.
For premium support please call: 800-290-4726 more ways to reach us
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter . [ 4 ]
Edwards Lifesciences (EW) closed the most recent trading day at $105.33, moving -0.58% from the previous trading session.
For premium support please call: 800-290-4726 more ways to reach us
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.